Britain on track for spring roll-out after Oxford vaccine results, researcher says

By: |
Updated: Nov 23, 2020 8:45 PM

Britain has secured 100 million doses of the AstraZeneca shot, 40 million of the Pfizer vaccine and 5 million of Moderna's candidate.

"I think we are on track for the timeline... to start getting this vaccine rolled out from December," Adrian Hill, director of Oxford's Jenner Institute, told Reuters"I think we are on track for the timeline... to start getting this vaccine rolled out from December," Adrian Hill, director of Oxford's Jenner Institute, told Reuters.

Britain is on track to make COVID-19 vaccines widely available by next spring after the shot developed by Oxford University and AstraZeneca was up to 90% effective in trials, the head of the university’s Jenner Institute said on Monday.

The encouraging late-stage trial results were the third published among the seven vaccine candidates Britain has ordered, following on from Pfizer/BioNTech and Moderna earlier this month.

“I think we are on track for the timeline … to start getting this vaccine rolled out from December,” Adrian Hill, director of Oxford University’s Jenner Institute that developed the vaccine, told Reuters.

Britain has secured 100 million doses of the AstraZeneca shot, 40 million of the Pfizer vaccine and 5 million of Moderna’s candidate.

British Prime Minister Boris Johnson has highlighted the prospect of vaccines as a reason for optimism that things could improve by spring, after he introduced a second national lockdown in England this month to tackle rising infections.

“It’s marvellous,” said 59-year-old Jo Canilleri. “Hopefully we won’t take that long before we can actually get it, because … a lot of people are just ignoring this. It’s not a thing that you can ignore. I mean look at the lives we’ve lost.”

In Britain 55,000 people have died from COVID-19, the highest death toll in Europe.

Hill said high-risk groups would receive the vaccine before it was rolled out to everyone in spring.

“I think that could be done. It’s going to be an enormous effort … hopefully there will be vaccine available for all adults, but that’s likely to be springtime rather than in January,” Hill said.

Back to Normal?
AstraZeneca executive Pam Cheng said there would be enough supplies of the active ingredient in the vaccine to provide Britain with 20 million doses by the end of the year and 70 million by the end of March.

She said that would translate into 4 million finished doses this year and 40 million by the end of March. The vaccine is also being manufactured by other AstraZeneca partners.

Britain’s health minister has asked the health service to be prepared to deliver vaccines from Dec. 1, although he said he expects the bulk of the roll-out to happen next year.

Initial late-stage trial results published on Monday showed that a regimen of two full doses was 62% effective in shielding people from COVID-19, though the efficacy rate jumped to 90% if the first shot was only half a normal dose.

Britain expects to receive 10 million doses of the Pfizer vaccine, which was 95% effective in trials, this year but the fact it needs to be stored at minus 70 degrees Celsius could pose logistical challenges for a mass roll-out.

Britain won’t receive any Moderna vaccines, which were 94.5% effective based on initial results, until next spring.

Andrew Pollard, director of the Oxford Vaccine Group and chief investigator into the trial, said the results for all the shots released so far showed they could help protect against severe cases of COVID-19, which in turn would help Britain’s National Health Service (NHS). “That, to me, means that, whichever of the vaccines we could deploy we’re likely to be able to prevent people going into hospital clogging up, in this country, the NHS and allow us to at least get that bit of the system back to normal,” he told Reuters.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Covid 19 vaccine in India: Zydus Cadila begins enrolment for Phase 3 trial of ZyCoV-D in 4 cities
2Vaccine hesitancy 39 per cent in Delhi-NCR: Survey
3Bird flu: FSSAI advises consumers not to eat undercooked chicken; says no need to panic